

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## Product

Name of Fund: **L&G Healthcare Breakthrough UCITS ETF**  
 Share class name: **USD Accumulating ETF**  
 Manufacturer name: LGIM Managers (Europe) Limited, part of the Legal & General Group  
 Share class ISIN: IE00BK5BC677

This PRIIP is authorised in Ireland  
 Website: <https://www.fundcentres.lgim.com/>  
 Telephone: +44 (0) 203 124 3277  
 Regulator: Central Bank of Ireland  
 Production date: 2022-12-26

## What is this product?


**Type:** This investment fund is a sub-Fund of Legal & General UCITS ETF Plc (the "Company"), an umbrella investment company with variable capital and segregated liability between Funds. The Fund is authorised in Ireland and regulated by the Central Bank of Ireland.

**Term:** There is no fixed maturity date.

**Objectives:** The Fund is a passively managed exchange traded Fund that is a passively managed exchange traded Fund ("ETF") that aims to track the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the "Index"), subject to the deduction of the ongoing charges and other costs associated with operating the Fund. The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Shares in this Share Class (the "Shares") are denominated in USD and can be bought and sold on stock exchanges by ordinary investors using an intermediary (e.g. a stockbroker). In normal circumstances, only Authorised Participants may buy and sell Shares directly with the Company. Authorised Participants may redeem their Shares on demand in accordance with the "Dealing Timetable" published on <http://www.lgim.com>. The Index is comprised of companies which are publically traded on various stock exchanges around the world that generate a proportion of their revenues from the healthcare technology industry. The industry is deemed to be comprised of the following nine subsectors: diagnostic, lab process automation, genomics, regenerative medicine, precision medicine, telehealth, data analytics, robotics and medical instruments. A company is only eligible for inclusion in the Index if it is of a sufficient size (determined by reference to the total market value of its shares) and it is sufficiently "liquid" (a measure of how actively its shares are traded on a daily basis). Within the Index, companies involved in the healthcare technology industry are assigned a score based on (a) a company's revenue from healthcare technology, (b) levels of investment in healthcare technology and (c) market positioning in the healthcare technology industry (the "Score"). Constituents are weighted according to their Score. The Fund will primarily invest in the companies contained in the Index in similar proportions to their weightings in the Index. The Fund may also invest in (1) "technology" companies that are not constituents of the Index that have similar risk and performance characteristics to the companies contained in the Index and (2) financial derivative instruments (i.e. investments the prices of which are based on the companies contained in the Index and/or such other companies). This Share Class does not intend to pay dividends. Any income which may result from the Fund's investments will be reinvested into the Fund.

**Intended retail investor:** The Fund is designed for investors looking to grow their money in an investment which can form part of their existing savings portfolio. Although investors can take their money out at any time, the Fund may not be appropriate for those who plan to withdraw their money within five years. The Fund is not designed for investors who cannot afford more than a minimal loss of their investment.

## What is the risk and what could I get in return?



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as class 6 out of 7, which is the second-highest risk class.

The Fund is subject to the risks associated with technology-focused companies that are particularly vulnerable to rapid developments in technology (which may leave their products out-of-date), government regulation and competition could negatively affect their value.

The value of the Fund may be affected by risks not in the SRI, including failure of a counterparty, custodian, issuer or index provider and derivative use.

## Performance scenarios

Investment USD 10,000			
Scenarios		1 year	5 years (Recommended holding period)
Stress scenario	What you might get back after costs	1,260.0 USD	770.0 USD
	Average return each year	-87.4%	-40.1%
Unfavourable scenario	What you might get back after costs	6,060.0 USD	6,060.0 USD
	Average return each year	-39.4%	-9.5%
Moderate scenario	What you might get back after costs	12,940.0 USD	30,610.0 USD
	Average return each year	29.4%	25.1%
Favourable scenario	What you might get back after costs	18,720.0 USD	53,000.0 USD
	Average return each year	87.2%	39.6%

Minimum: There is no minimum guaranteed return. You could lose some or all of your investment.

Unfavourable scenario: 2021-06-30 to 2022-06-30

Moderate scenario: 2015-05-31 to 2020-05-31

Favourable scenario: 2016-01-31 to 2021-01-31

This table shows the money you could get back over the next 5 year(s), under different scenarios, assuming that you invest 10,000.00 USD.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product over the last 10 years. The scenarios shown are illustrations based on results from the past and on certain assumptions. Markets could develop very differently in the future.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

**Market developments in the future cannot be accurately predicted. The scenarios shown are only an indication of some of the possible outcomes based on recent returns. Actual returns could be lower.**

## What happens if LGIM Managers (Europe) Limited is unable to pay out?

If LGIM Managers (Europe) Limited defaults, investors in the Fund would not face any financial losses. However, the value of an investment and any income taken from it is not guaranteed and can go down as well as up, you may not get back the amount you originally invested. The fund is not covered by an investor compensation scheme.

## What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for the holding period(s). They include potential early exit penalties. The figures assume you invest 10,000.00 USD. The figures are estimates and may change in the future.

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

These figures include the maximum distribution fee that the person selling you the product may charge. This person will inform you of the actual distribution fee.

We have assumed:

- In the first year you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- USD 10,000/1,000 per year is invested.

Investment USD 10,000	If you cash in after 1 year	If you cash in after 5 years
Total costs	111.00 USD	1,737.00 USD
Impact on return (RIY) per year	1.11%	1.39%

## Composition of costs

The table below shows:

- The impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period.
- What the different cost categories mean.

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	0.00% There is no entry fee for this product.	0.00 USD
Exit costs	0.00% There is no exit fee for this product.	0.00 USD
Ongoing costs taken each year		
Management fees and other administrative or operating costs	0.49% of the value of your investment per year.	49.00 USD
Transaction costs	0.61% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	60.80 USD
Incidental costs taken under specific conditions		
Performance fees and carried interest	0.00% There is no performance fee for this product.	0.00 USD

## How long should I hold it and can I take my money out early?

An investor can hold their investment for any time period but 5 year(s) is recommended.

The recommended holding period of 5 years has been selected for illustrative purposes only. Equity investments should be seen as long-term investments however there is no minimum (or maximum) holding period for the Shares. The Shares can be sold by ordinary investors using an intermediary (e.g. a stockbroker) when the markets on which they trade are open. An intermediary is likely to apply a commission to purchases and sales.

The above mentioned period has been defined in accordance to the product characteristics.

## How can I complain?

Complaints can be made in writing to [complaints@lgim.com](mailto:complaints@lgim.com) or to LGIM Managers (Europe) Ltd, 70 Sir John Rogerson's Quay, Dublin 2, DO2 R296, Ireland.

## Other relevant information

Further information about the Fund including previous performance scenarios required under PRIIPs regulation can be found at [www.lgim.com](http://www.lgim.com). There is insufficient data to provide a useful indication of past performance. The Fund's Prospectus and the annual and semi-annual reports can also be found there in English and certain other languages. This Key Investor Document is updated at least every 12 months. If you are in any doubt about the action you should take, you should seek independent financial advice.